

HHS Public Access

J Diabetes Complications. Author manuscript; available in PMC 2018 May 01.

Published in final edited form as:

Author manuscript

J Diabetes Complications. 2017 May ; 31(5): 787–795. doi:10.1016/j.jdiacomp.2017.03.002.

Androgen receptor-deficient islet β-cells exhibit alteration in genetic markers of insulin secretion and inflammation. A transcriptome analysis in the male mouse

Weiwei Xu¹, Tianhua Niu², Beibei Xu¹, Guadalupe Navarro³, Matthew J. Schipma³, and Franck Mauvais-Jarvis¹

¹Diabetes Discovery Research and Gender Medicine Laboratory, Department of Medicine, Section of Endocrinology and Metabolism, Tulane University School of Medicine, New Orleans

²Department of Biostatistics and Bioinformatics, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA 70112, USA

³Department of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA

Abstract

Aims—Testosterone action is mediated via the androgen receptor (AR). We have reported that male mice lacking AR selectively in β -cells (β ARKO^{-/y}) develop decreased glucose-stimulated insulin secretion (GSIS), producing glucose intolerance. We showed that testosterone action on AR in β -cells amplifies the insulinotropic action of GLP-1 on its receptor via a cAMP- dependent protein kinase-A pathway.

Methods—To investigate AR-dependent gene networks in β -cells, we performed a high throughput whole transcriptome sequencing (RNA-Seq) in islets from male β ARKO^{-/y} and control mice.

Results—We identified 214 differentially expressed genes (DEGs) (158 up- and 56 downregulated) with a false discovery rate (FDR) < 0.05 and a fold change (FC) > 2. Our analysis of individual transcripts revealed alterations in β -cell genes involved in cellular inflammation/stress and insulin secretion. Based on 312 DEGs with an FDR < 0.05, the pathway analysis revealed 23 significantly enriched pathways, including cytokine-cytokine receptor interaction, Jak-STAT signaling, insulin signaling, MAPK signaling, type 2 diabetes (T2D) and pancreatic secretion. The gene ontology analysis confirmed the results of the individual DEGs and the pathway analysis in showing enriched biological processes encompassing inflammation, ion transport, exocytosis and insulin secretion.

^{*}To whom correspondence should be addressed at: Franck Mauvais-Jarvis, MD, PhD, Price-Goldsmith Chair and Professor of Medicine, Diabetes Discovery Research and Gender Medicine Laboratory, Department of Medicine, Section of Endocrinology and Metabolism, Tulane University Health Sciences Center, New Orleans, LA 70112, USA. Tel: 504-988-5990; Fax: 504-988-6271; fmauvais@tulane.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Androgen receptor; Type 2 Diabetes; Pancreatic β-cell; RNA-Seq; transcriptome

1. Introduction

The aging of the U.S. male population will cause a large increase in the burden of clinically symptomatic androgen deficiency, which currently represents 18% of men over 70 years old (Araujo et al., 2007). In addition, prostate cancer is the most common malignancy in men, and androgen deprivation therapy (ADT), the standard of treatment, produces severe testosterone deficiency. Treatment of the metabolic complications of ADT is now considered a clinical challenge (Navarro, Allard, Xu, & Mauvais-Jarvis, 2015; Yu, Lin, Sparks, Yeh, & Chang, 2014; Zitzmann, 2009). The impact of testosterone deficiency on the development of visceral obesity and insulin resistance in men is well established (Navarro et al., 2015; Zitzmann, 2009). In contrast, and surprisingly, the role of testosterone deficiency in β -cell dysfunction remains poorly explored. This remarkable lack of knowledge is particularly surprising because previous research has implicated low testosterone levels in the pathogenesis of hyperglycemia in men (Mauvais-Jarvis, 2016a). Men with prostate cancer treated with ADT, and therefore exhibiting primary testosterone depletion, are predisposed to diabetes. In two large population-based studies of men with prostate cancer, ADT was associated with a 28% to 44% increased risk of incident T2D compared to controls (Keating, O'Malley, Freedland, & Smith, 2010; Keating, O'Malley, & Smith, 2006). Mice lacking AR globally are also hyperglycemic and exhibit decreased GSIS (Dubois et al., 2016).

To assess the role of AR in β -cell function in the male, we previously generated male mice lacking AR selectively in β -cells (β ARKO^{-/y}). These mice develop decreased glucosestimulated insulin secretion (GSIS) without alteration in β -cell mass but producing glucose intolerance (Navarro et al., 2016). When these mice are exposed to a western diet, they are hyperglycemic and hypoinsulinemic in the fasted and fed states. We reported that testosterone action on AR β -cells amplifies the insulinotropic action of GLP-1 on its receptor via a cAMP-dependent protein kinase-A pathway (Navarro et al., 2016). Thus, androgen deficiency predisposes to T2D via the combination of loss of androgen action in peripheral tissues producing insulin resistance and loss of androgen action in β -cells producing β -cell failure to compensate for insulin resistance (Mauvais-Jarvis, 2016b; Navarro et al., 2015; Navarro et al., 2016).

To gain further insight on the role of AR in male β -cells though AR-dependent gene networks, we performed a high throughput whole transcriptome sequencing (RNA-Seq) in islets from male β ARKO^{-/y} and control mice.

2. Material and Methods

2.1 Generation of Mutant Mice

The β ARKO ^{/y} mouse was generated by crossing mice carrying the AR gene with floxed exon 2 on their X chromosome (AR^{lox}) with transgenic mice with the Cre recombinase expression under rat insulin II promoter (RIP-Cre, Jackson Laboratory) as previously described (Navarro et al., 2016).

2.2 Islet Isolation and RNA Preparation

Islet isolation was performed following pancreatic duct injection with collagenase as previously described (Tiano et al., 2011). Islets were isolated from 3 male ARlox^{-/y} mice and 3 RIP-Cre mice and immediately frozen in liquid nitrogen (Fig. 1). Mice were at 12-week of age at the time of islet isolation, and were fed on the normal chow. The metabolic parameters of mice at the same age were previously described (Navarro et al., 2016). Total RNA was extracted using RNeasy Maxi Kit (Qiagen) following the manufacturer's recommendations, and the samples were sent to NUseq Core, Northwestern University for RNA sequencing.

2.3 RNA-Seq Analysis

The quality of DNA reads, in FASTQ format, was evaluated using FastQC (http:// www.bioinformatics.babraham.ac.uk/projects/fastqc/). Adapters were removed and reads of inadequate quality were filtered. The raw read data was processed largely following the procedure described in (Trapnell et al., 2012). Briefly, the reads were aligned to the *Mus musculus* genome (mm10) using TopHat (v2.0.8b). Subsequently, the aligned reads, in conjunction with a gene annotation file for mm10 obtained from the University of California Santa Cruz (UCSC) website (http://genome.ucsc.edu/), were used to determine RNA expressions of annotated genes using Cufflinks (v2.1.1).

2.4 Single-Gene Analysis

For a transcript g, the expression level is estimated by the number of reads (C_g) mapped to the region of the transcript normalized by the length (L) of the transcript in nucleotides and the total number (N) of mapped reads of the mouse genome. If we use kilobase as the unit for L and million reads as the unit for N, this estimation is called reads per kilobase of transcript per million mapped reads (RPKM), which is the most widely used RNA-seq normalization method (Li, Piao, Shon, & Ryu, 2015). The individual transcript files generated by Cufflinks for each sample were merged into a single gene annotation file, which was then used to perform a DE analysis with the Cufflinks routine, Cuffdiff. Significant DEGs were determined by Cuffdiff using the procedure described in (Trapnell et al., 2012) based on a Benjamini-Hochberg false discovery rate (FDR) threshold of 0.05 (Reiner, Yekutieli, & Benjamini, 2003). Results of such differential expression analysis were processed with CummeRbund (Trapnell et al., 2012). The significant DEGs were separated into those that were up-regulated and those that were down-regulated.

2.5 Quantitative Reverse Transcription PCR (qRT-PCR)

Total RNA was extracted from MIN6 cells with RNeasy Plus Mini Kit (Qiagen) following the manufacturer's instructions. The quality and concentration of RNA were assessed by NanoDrop Spectrophotometer (Thermo Scientific). RNA was reverse transcribed into cDNA using iScript cDNA Synthesis Kit (Bio-Rad). Quantification of targeted genes was performed using iTaq Universal SYBRR Green Supermix (Bio-Rad) and the iCycler iQ Real Time PCR Detection System (Bio-Rad). Ct values were normalized to TBP and the relative gene expression was calculated with the 2⁻ Ct method. Gene-specific KiCqStart primers were purchased from Sigma-Aldrich as listed in Supplemental Table 1.

2.6 Pathway and Gene Ontology (GO) Analysis

The list of 312 (225 up- and 87 down-regulated) significant DEGs (FDR < 0.05) were analyzed by applying (i) GeneCodis3 (http://genecodis.cnb.csic.es) (Tabas-Madrid, Nogales-Cadenas, & Pascual-Montano, 2012) and (ii) GeneTrail (http://genetrail.bioinf.uni-sb.de/) (Backes et al., 2007) software tools to identify significantly enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and GO categories by over-representation analysis.

2.7 Statistical Analysis

Results are presented as mean \pm SEM in Fig. 4. All statistical analyses were performed using the unpaired Student's *t* test. A P value less than 0.05 was considered statistically significant. ** P<0.01, *** P<0.001.

3. Results

3.1 Single-Gene Analysis

A total of 23,179 genes were annotated with RefSeq IDs. Of these, a fold change (FC) (defined as the relative ratio of gene expression between $\beta ARKO^{-/y}$ to control islets) could be computed for 22,061 genes. Among these genes, 312 differentially expressed genes (DEGs) (225 up- and 87 down-regulated) were discovered at a false discovery rate (FDR) < 0.05. At FDR < 0.05 and FC > 2, a total of 214 significant DEGs (158 were up- and 56 down-regulated) were identified (Supplemental Table 2). Of these DEGs, 66 were associated with inflammation and stress (53 up- and 13 down-regulated) (Table 1), and 56 were associated with β -cell insulin secretion including metabolism, cAMP-PKA signaling, ion channels, Ras-related protein/GTPase, glucose metabolism, membrane polarization, and secreted factor (44 up- and 12 down-regulated) (Table 2). Thus, in βARKO^{-/y} islets, 31% of the DEGs were associated with β-cell inflammation and stress, and 26% with insulin secretion (Fig. 2). We validated a set of individual gene expression results by qRT-PCR in cultured MIN-6 insulin-producing cells treated with the pure AR agonist dihydrotestosterone (DHT) (Fig. 3). Mirroring the results obtained in control and βARKO^{-/y} islets, DHT suppressed the mRNA for hepatokine fibroblast growth factor 21 (Fgf21), the innate immune molecule lipocalin 2 (Lcn2), syntrophin, gamma 2 (Sntg2), G-protein-coupled receptor (GPR) 26 (Gpr26), and Gpr119. No effect of DHT was observed for dual oxidase 2 (Duox2), and the transient receptor potential cation channel, subfamily C, member 4 (Trpc4).

3.2 Pathway Analysis

Gene expression analyzed on a gene-by-gene basis ignores the underlying biological structure and diminishes the power of analysis, obscuring the presence of important biological signals (Haynes, Higdon, Stanberry, Collins, & Kolker, 2013). Thus, grouping genes by biological pathways is often the most relevant approach, because it takes into account the cooperative nature of genes and considers that genes involved in the same process are dysregulated together. Such an approach yields more robust results and may reveal novel insights about molecular mechanisms of disease (Lee, Chuang, Kim, Ideker, & Lee, 2008). The 312 DEGs at FDR < 0.05 were interpreted in a biological pathway context. Based on GeneCodis3 analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, 23 significantly enriched pathways were revealed (Table 3). The representative pathways are cytokine-cytokine receptor interaction (Kegg: 04060), Jak-STAT signaling pathways (Kegg: 04630), MAPK signaling pathway (Kegg: 04010), insulin signaling pathway (Kegg: 04910), and pancreatic secretion (Kegg: 04972). Based on the KEGG pathway results and our analysis of the literature, we combined these pathways and summarized them into three biologically relevant pathways: insulin secretion (Fig. 4A), stress/growth factor signaling (Fig. 4B), and inflammatory pathways (Fig. 4C).

3.3 Gene Ontology (GO) Analysis

Ontologies provide a formal representation of knowledge that is amenable to computational as well as human analysis, an obvious underpinning of systems biology (Thomas, Mi, & Lewis, 2007). The GO, like other formal ontologies, consists of a structured hierarchical controlled vocabulary for standardizing representations of gene and gene product attributes in relation to a large and growing context of biological knowledge (Boyle et al., 2004). Scientists have used GO terms to evaluate the characteristics of sets of genes (Consortium, 2017). The GO classifies gene functions into three categories: biological process (BP), cellular component (CC), and molecular function (MF) (Table 4). For the 312 significant DEGs, based on GeneCodis3 and GeneTrail analyses of GO categories, 43 BP, 17 CC, and 23 MF categories were identified (selection criteria: # genes in GO category 2 and FDR < 0.05 for both programs). For BP, representative categories included inflammatory response (GO: 0006954), ion transport (GO: 0006811), insulin secretion (GO: 0030073), negative regulation of signal transduction (GO: 0009968), apoptosis (GO: 0006915), cell adhesion (GO: 0007155), regulation of growth (GO: 0040008), and response to stress (GO: 0006950), indicating alteration in the β -cell function and stress. For CC, significantly enriched categories included extracellular region (GO: 0005576), integral to membrane (GO: 0016021), voltage-gated potassium channel complex (GO: 0008076), and integral to plasma membrane (GO: 00058887), revealing structural alterations in membrane proteins involved in insulin secretion. For MF, enriched categories were GTPase activity (GO: 0003924), calcium ion binding (GO: 0005509), GTP binding (GO: 0005525), hexokinase activity (GO: 0004396), transporter activity (GO: 0005215), ion channel activity (GO: 0005216), voltagegated potassium channel activity (GO: 0005249), and potassium channel activity (GO: 0005267), also indicating functional changes in β -cell secretory capacity.

4. Discussion

Using islets from adult male β ARKO^{-/y} mice, we identified 214 dysregulated genes involved in β-cell insulin secretion and stress, confirming that AR plays a vital role in male β -cell health. A third of these genes are coding for proteins mediating or responding to inflammation and cellular stress, demonstrating that islets with prolonged AR deficiency are injured and suffering. These include genes coding for Fgf21 (Wente et al., 2006), Lcn2 (Chang, Kim, Ko, Jo, & Kim, 2013), the member of the tumor necrosis factor receptor superfamily osteoprotegerin (tnfrsf11b) (Maruyama et al., 2006; Reid & Holen, 2009), chemokine ligands 5 and 10 (Cxcl5 and Cxcl10) (Nunemaker et al., 2014; Schulthess et al., 2009), several interferon (IFN)-gamma-induced guanylate-binding proteins (Gbp4, Gbp 5, Gbp 6, Gbp 8, Gbp 9, Gbp 10, and Gbp 11) (Kim et al., 2016), intra islet pro-inflammatory cytokines and associated receptors like interleukin-1 β (*II1b*), the interleukin 22 receptor- α 1 (II22ra1) (Shioya, Andoh, Kakinoki, Nishida, & Fujiyama, 2008), the IL-1 receptor antagonist (II1rn) (Dayer-Metroz, Wollheim, Seckinger, & Dayer, 1989) and interleukin-10 (IIIO) (Russell & Morgan, 2014). The coagulation factor XIII, A1 subunit (F13a1) has also been implicated in chronic low-grade inflammatory islets in T2D subjects (Sharma et al., 2015).

The second finding is that 20% of dysregulated genes are involved in β -cell function. These include genes coding for GPRs such as *Gpr161* (Bachmann et al., 2016), *Gpr126* (Mogha et al., 2013), *Gpr26* (Zhang et al., 2011), ion channels altering membrane polarization like the potassium inwardly-rectifying channel, subfamily J, member 5 (*kcnj5*), the potassium voltage-gated channel, subfamily Q, member 1 (*kcnq1*) (33), and *trpc4* (Islam, 2011), as well as proteins involved in β -cell exocytosis machinery such as the Ca(2+)-sensor synaptotagmin-10 (*Syt10*) (Cao, Maximov, & Sudhof, 2011), the GTP binding protein rabphilin 3a (*Rph3a*) (Arribas, Regazzi, Garcia, Wollheim, & De Camilli, 1997), heparan sulfate (glucosamine) 3-O-sulfotransferase 1 (*Hs3st1*) (Takahashi, Ohashi, & Nata, 2012) and enzymes involved in glucose metabolism, hexokinase 2 (*hk2*), hexokinase domain containing 1 (*hkdc1*) (Ludvik et al., 2016), glucokinase binding protein 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (*Pfkfb3*) (Arden et al., 2008) and zinc transport in β cells like the zinc transporter, member 4 (*Slc39a4*) (Hardy et al., 2015).

Dysregulated genes seem to fall into two categories. Some are detrimental to β -cell health and could be instrumental in impairing GSIS. For example, genome-wide association studies identified *Kcnq1* and *Rasgrp1* (RAS guanyl releasing protein 1) as susceptible genes for T2DM (Yasuda et al., 2008; Zeng et al., 2016) and β ARKO^{-/y} islets exhibit increased expression of both. *Kcnq1* impairs insulin secretion by enhancing the β -cell potassium currents (Yamagata et al., 2011). Increased expression of *Nr0b2* in β ARKO^{-/y} islets, coding the orphan nuclear receptor small heterodimer partner (SHP), is also expected to impair insulin gene transcription and decrease GSIS (Park et al., 2007) while increased *Car2* expression (carbonic anhydrase 2) (Yamato, Tashiro, & Miyazaki, 2013) is a genetic marker of poor GSIS, and increased *Sostdc1* (sclerostin domain containing 1) expression inhibits Bmp and Wnt which impairs β -cell function (Henley, Gooding, Economides, & Gannon, 2012). Other adverse upregulated genes include *lcn2*, induced in β -cells by inflammatory cytokines (Chang et al., 2013), the chemokines (*Cxcl5* and *Cxcl10*) increased in islets from

T2D humans and rodents and which are known to impair β -cell function and survival (Nunemaker et al., 2014; Schulthess et al., 2009), and multiple GBPs that activate the inflammasome and produce β -cell inflammation (Kim et al., 2016).

In contrast, another set of dysregulated genes seems to be part of a concerted compensatory mechanism attempting to preserve β -cell function from the deleterious effect of the AR knockout. For example, increased expression of *Fgf21* (Wente et al., 2006) or *Il1rn* (IL-1 β receptor antagonist) (Dayer-Metroz et al., 1989) is expected to protect islet function and survival during inflammation, and the increased *Hs3st1* expression is expected to enhance GSIS (Takahashi et al., 2012). Other adaptive mechanisms include increased expression of genes coding for proteins that could enhance GSIS by increasing β -cell glucose metabolism (*Hk2, Pfkfb3*) (Ludvik et al., 2016), cAMP production (*Gpr119, Gpr26, GPR126, Gpr161,* activating transcription factor 3, (*Atf3*)), insulin vesicle exocytosis (*Syt10, Rph3a*), and β -cell membrane depolarization (*Trpc4*) (Islam, 2011).

Our pathway analysis revealed 23 significantly enriched pathways that we combined into two biologically relevant pathways, inflammatory pathways and insulin secretion, confirming our observation from individually dysregulated genes. Ontologies used to evaluate the characteristics of differentially expressed genes in β ARKO^{-/y} islets were also enriched for GO terms "response to stress," "inflammatory response," "apoptosis," "insulin secretion," "ion transport," and "cell adhesion." Taken together, these results of GO analysis confirmed the results of the pathway analysis and our individual gene evaluation that AR deficiency promotes β -cell dysfunction and inflammation. Consistent with our findings, testosterone protects early apoptotic damage induced by streptozotocin in male rat pancreas through AR suggesting that AR activation may protect male islets from inflammation (Morimoto et al., 2005; Palomar-Morales, Morimoto, Mendoza-Rodriguez, & Cerbon, 2010). In addition, neuronal specific AR-deficient mice exhibit hypothalamic inflammation via activation of nuclear factor- κ B (Yu et al., 2013) which promotes obesity, insulin resistance and glucose intolerance.

A limitation of the present study is that we did not validate all our individual gene expression results by qRT-PCR. However, previous studies have reported high consistencies between RNA-seq and qRT-PCR results (Trost et al., 2015). RNA-seq shows both high reproducibility and low frequency of false positives (Richard et al., 2010) and has been used for transcriptional profiling of specific cell types or tissues at unprecedented precision (Schmid et al., 2012).

In conclusion, a transcriptome analysis of islets from adult male β ARKO^{-/y} mice revealed alterations in genes involved in inflammation and insulin secretion, demonstrating the importance of androgen action in β -cell health in males, with implications for the development of T2D in androgen deficient men.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by grants from the National Institutes of Health (grant numbers DK074970, DK107444), the American Diabetes Association (grant number 7-13-BS-101) and in part from LA CaTS Center (grant number1 U54 GM104940).

References

- Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, ... McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007; 92(11): 4241–4247. DOI: 10.1210/jc.2007-1245 [PubMed: 17698901]
- Arden C, Hampson LJ, Huang GC, Shaw JA, Aldibbiat A, Holliman G, ... Agius L. A role for PFK-2/ FBPase-2, as distinct from fructose 2,6-bisphosphate, in regulation of insulin secretion in pancreatic beta-cells. Biochem J. 2008; 411(1):41–51. DOI: 10.1042/BJ20070962 [PubMed: 18039179]
- Arribas M, Regazzi R, Garcia E, Wollheim CB, De Camilli P. The stimulatory effect of rabphilin 3a on regulated exocytosis from insulin-secreting cells does not require an association-dissociation cycle with membranes mediated by Rab 3. Eur J Cell Biol. 1997; 74(3):209–216. Retrieved from http:// www.ncbi.nlm.nih.gov/pubmed/9402469. [PubMed: 9402469]
- Bachmann VA, Mayrhofer JE, Ilouz R, Tschaikner P, Raffeiner P, Rock R, ... Stefan E. Gpr161 anchoring of PKA consolidates GPCR and cAMP signaling. Proc Natl Acad Sci U S A. 2016; 113(28):7786–7791. DOI: 10.1073/pnas.1608061113 [PubMed: 27357676]
- Backes C, Keller A, Kuentzer J, Kneissl B, Comtesse N, Elnakady YA, ... Lenhof HP. GeneTrail-advanced gene set enrichment analysis. Nucleic Acids Res. 2007; 35(Web Server issue):W186–192. DOI: 10.1093/nar/gkm323 [PubMed: 17526521]
- Boyle EI, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, Sherlock G. GO::TermFinder--open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics. 2004; 20(18):3710–3715. DOI: 10.1093/bioinformatics/bth456 [PubMed: 15297299]
- Cao P, Maximov A, Sudhof TC. Activity-dependent IGF-1 exocytosis is controlled by the Ca(2+)sensor synaptotagmin-10. Cell. 2011; 145(2):300–311. DOI: 10.1016/j.cell.2011.03.034 [PubMed: 21496647]
- Chang SY, Kim DB, Ko SH, Jo YH, Kim MJ. Induction mechanism of lipocalin-2 expression by costimulation with interleukin-1beta and interferon-gamma in RINm5F beta-cells. Biochem Biophys Res Commun. 2013; 434(3):577–583. DOI: 10.1016/j.bbrc.2013.03.117 [PubMed: 23583381]
- Consortium, T. G. O. Expansion of the Gene Ontology knowledgebase and resources. Nucleic Acids Res. 2017; 45(D1):D331–d338. DOI: 10.1093/nar/gkw1108 [PubMed: 27899567]
- Dayer-Metroz MD, Wollheim CB, Seckinger P, Dayer JM. A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. J Autoimmun. 1989; 2(2):163–171. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2527507.
- Dubois V, Laurent MR, Jardi F, Antonio L, Lemaire K, Goyvaerts L, ... Claessens F. Androgen Deficiency Exacerbates High-Fat Diet-Induced Metabolic Alterations in Male Mice. Endocrinology. 2016; 157(2):648–665. DOI: 10.1210/en.2015-1713 [PubMed: 26562264]
- Hardy AB, Prentice KJ, Froese S, Liu Y, Andrews GK, Wheeler MB. Zip4 mediated zinc influx stimulates insulin secretion in pancreatic beta cells. PLoS One. 2015; 10(3):e0119136.doi: 10.1371/journal.pone.0119136 [PubMed: 25806541]
- Haynes WA, Higdon R, Stanberry L, Collins D, Kolker E. Differential expression analysis for pathways. PLoS Comput Biol. 2013; 9(3):e1002967.doi: 10.1371/journal.pcbi.1002967 [PubMed: 23516350]
- Henley KD, Gooding KA, Economides AN, Gannon M. Inactivation of the dual Bmp/Wnt inhibitor Sostdc1 enhances pancreatic islet function. Am J Physiol Endocrinol Metab. 2012; 303(6):E752– 761. DOI: 10.1152/ajpendo.00531.2011 [PubMed: 22829579]
- Islam MS. TRP channels of islets. Adv Exp Med Biol. 2011; 704:811–830. DOI: 10.1007/978-94-007-0265-3_42 [PubMed: 21290328]

- Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010; 102(1):39–46. DOI: 10.1093/jnci/djp404 [PubMed: 19996060]
- Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24(27):4448–4456. DOI: 10.1200/ JCO.2006.06.2497 [PubMed: 16983113]
- Kim BH, Chee JD, Bradfield CJ, Park ES, Kumar P, MacMicking JD. Interferon-induced guanylatebinding proteins in inflammasome activation and host defense. Nat Immunol. 2016; 17(5):481– 489. DOI: 10.1038/ni.3440 [PubMed: 27092805]
- Lee E, Chuang HY, Kim JW, Ideker T, Lee D. Inferring pathway activity toward precise disease classification. PLoS Comput Biol. 2008; 4(11):e1000217.doi: 10.1371/journal.pcbi.1000217 [PubMed: 18989396]
- Li P, Piao Y, Shon HS, Ryu KH. Comparing the normalization methods for the differential analysis of Illumina high-throughput RNA-Seq data. BMC Bioinformatics. 2015; 16:347.doi: 10.1186/ s12859-015-0778-7 [PubMed: 26511205]
- Ludvik AE, Pusec CM, Priyadarshini M, Angueira AR, Guo C, Lo A, ... Layden BT. HKDC1 Is a Novel Hexokinase Involved in Whole-Body Glucose Use. Endocrinology. 2016; 157(9):3452–3461. DOI: 10.1210/en.2016-1288 [PubMed: 27459389]
- Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, Matsuo K. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol. 2006; 177(6):3799–3805. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/ 16951341. [PubMed: 16951341]
- Mauvais-Jarvis F. Androgen-deprivation therapy and pancreatic beta-cell dysfunction in men. J Diabetes Complications. 2016a; 30(3):389–390. DOI: 10.1016/j.jdiacomp.2016.01.007 [PubMed: 26861947]
- Mauvais-Jarvis F. Role of Sex Steroids in beta Cell Function, Growth, and Survival. Trends Endocrinol Metab. 2016b; doi: 10.1016/j.tem.2016.08.008
- Mogha A, Benesh AE, Patra C, Engel FB, Schoneberg T, Liebscher I, Monk KR. Gpr126 functions in Schwann cells to control differentiation and myelination via G-protein activation. J Neurosci. 2013; 33(46):17976–17985. DOI: 10.1523/JNEUROSCI.1809-13.2013 [PubMed: 24227709]
- Morimoto S, Mendoza-Rodriguez CA, Hiriart M, Larrieta ME, Vital P, Cerbon MA. Protective effect of testosterone on early apoptotic damage induced by streptozotocin in rat pancreas. J Endocrinol. 2005; 187(2):217–224. 187/2/217 [pii]. DOI: 10.1677/joe.1.06357 [PubMed: 16293769]
- Navarro G, Allard C, Xu W, Mauvais-Jarvis F. The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring). 2015; 23(4):713–719. DOI: 10.1002/oby. 21033 [PubMed: 25755205]
- Navarro G, Xu W, Jacobson DA, Wicksteed B, Allard C, Zhang G, ... Mauvais-Jarvis F. Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male. Cell Metab. 2016; 23(5):837–851. DOI: 10.1016/j.cmet.2016.03.015 [PubMed: 27133133]
- Nunemaker CS, Chung HG, Verrilli GM, Corbin KL, Upadhye A, Sharma PR. Increased serum CXCL1 and CXCL5 are linked to obesity, hyperglycemia, and impaired islet function. J Endocrinol. 2014; 222(2):267–276. DOI: 10.1530/JOE-14-0126 [PubMed: 24928936]
- Palomar-Morales M, Morimoto S, Mendoza-Rodriguez CA, Cerbon MA. The protective effect of testosterone on streptozotocin-induced apoptosis in beta cells is sex specific. Pancreas. 2010; 39(2):193–200. DOI: 10.1097/MPA.0b013e3181c156d9 [PubMed: 20093993]
- Park KG, Lee KM, Seo HY, Suh JH, Kim HS, Wang L, ... Lee IK. Glucotoxicity in the INS-1 rat insulinoma cell line is mediated by the orphan nuclear receptor small heterodimer partner. Diabetes. 2007; 56(2):431–437. DOI: 10.2337/db06-0753 [PubMed: 17259388]
- Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009; 88(1):1–17. DOI: 10.1016/j.ejcb.2008.06.004 [PubMed: 18707795]
- Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 2003; 19(3):368–375. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12584122. [PubMed: 12584122]

- Richard H, Schulz MH, Sultan M, Nurnberger A, Schrinner S, Balzereit D, ... Yaspo ML. Prediction of alternative isoforms from exon expression levels in RNA-Seq experiments. Nucleic Acids Res. 2010; 38(10):e112.doi: 10.1093/nar/gkq041 [PubMed: 20150413]
- Russell MA, Morgan NG. The impact of anti-inflammatory cytokines on the pancreatic beta-cell. Islets. 2014; 6(3):e950547.doi: 10.4161/19382014.2014.950547 [PubMed: 25322830]
- Schmid MW, Schmidt A, Klostermeier UC, Barann M, Rosenstiel P, Grossniklaus U. A powerful method for transcriptional profiling of specific cell types in eukaryotes: laser-assisted microdissection and RNA sequencing. PLoS One. 2012; 7(1):e29685.doi: 10.1371/journal.pone. 0029685 [PubMed: 22291893]
- Schulthess FT, Paroni F, Sauter NS, Shu L, Ribaux P, Haataja L, ... Maedler K. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab. 2009; 9(2):125–139. DOI: 10.1016/j.cmet.2009.01.003 [PubMed: 19187771]
- Sharma PR, Mackey AJ, Dejene EA, Ramadan JW, Langefeld CD, Palmer ND, ... Nunemaker CS. An Islet-Targeted Genome-Wide Association Scan Identifies Novel Genes Implicated in Cytokine-Mediated Islet Stress in Type 2 Diabetes. Endocrinology. 2015; 156(9):3147–3156. DOI: 10.1210/en.2015-1203 [PubMed: 26018251]
- Shioya M, Andoh A, Kakinoki S, Nishida A, Fujiyama Y. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas. 2008; 36(2):197–199. DOI: 10.1097/MPA.0b013e3181594258 [PubMed: 18376313]
- Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A. GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res. 2012; 40(Web Server issue):W478–483. DOI: 10.1093/nar/gks402 [PubMed: 22573175]
- Takahashi I, Ohashi K, Nata K. Involvement of heparan sulfate 3-O-sulfotransferase isoform-1 in the insulin secretion pathway. J Diabetes Investig. 2012; 3(4):362–370. DOI: 10.1111/j. 2040-1124.2012.00205.x
- Thomas PD, Mi H, Lewis S. Ontology annotation: mapping genomic regions to biological function. Curr Opin Chem Biol. 2007; 11(1):4–11. DOI: 10.1016/j.cbpa.2006.11.039 [PubMed: 17208035]
- Tiano JP, Delghingaro-Augusto V, Le May C, Liu S, Kaw MK, Khuder SS, ... Mauvais-Jarvis F. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents beta cell failure in rodent models of type 2 diabetes. J Clin Invest. 2011; 121(8):3331–3342. 44564 [pii]. DOI: 10.1172/JCI44564 [PubMed: 21747171]
- Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, ... Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012; 7(3):562–578. DOI: 10.1038/nprot.2012.016 [PubMed: 22383036]
- Trost B, Moir CA, Gillespie ZE, Kusalik A, Mitchell JA, Eskiw CH. Concordance between RNAsequencing data and DNA microarray data in transcriptome analysis of proliferative and quiescent fibroblasts. R Soc Open Sci. 2015; 2(9):150402.doi: 10.1098/rsos.150402 [PubMed: 26473061]
- Wente W, Efanov AM, Brenner M, Kharitonenkov A, Koster A, Sandusky GE, ... Gromada J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006; 55(9):2470– 2478. DOI: 10.2337/db05-1435 [PubMed: 16936195]
- Yamagata K, Senokuchi T, Lu M, Takemoto M, Fazlul Karim M, Go C, ... Song WJ. Voltage-gated K+ channel KCNQ1 regulates insulin secretion in MIN6 beta-cell line. Biochem Biophys Res Commun. 2011; 407(3):620–625. DOI: 10.1016/j.bbrc.2011.03.083 [PubMed: 21426901]
- Yamato E, Tashiro F, Miyazaki J. Microarray analysis of novel candidate genes responsible for glucose-stimulated insulin secretion in mouse pancreatic beta cell line MIN6. PLoS One. 2013; 8(4):e61211.doi: 10.1371/journal.pone.0061211 [PubMed: 23560115]
- Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, ... Kasuga M. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet. 2008; 40(9):1092–1097. DOI: 10.1038/ng.207 [PubMed: 18711367]
- Yu IC, Lin HY, Liu NC, Sparks JD, Yeh S, Fang LY, ... Chang C. Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-kappaB-mediated PTP1B expression. Diabetes. 2013; 62(2):411–423. DOI: 10.2337/db12-0135 [PubMed: 23139353]

- Yu IC, Lin HY, Sparks JD, Yeh S, Chang C. Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes. 2014; 63(10):3180–3188. DOI: 10.2337/db13-1505 [PubMed: 25249645]
- Zeng H, Guo M, Zhou T, Tan L, Chong CN, Zhang T, ... Chen S. An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery. Cell Stem Cell. 2016; 19(3):326–340. DOI: 10.1016/j.stem.2016.07.002 [PubMed: 27524441]
- Zhang LL, Wang JJ, Liu Y, Lu XB, Kuang Y, Wan YH, ... Wang ZG. GPR26-deficient mice display increased anxiety- and depression-like behaviors accompanied by reduced phosphorylated cyclic AMP responsive element-binding protein level in central amygdala. Neuroscience. 2011; 196:203– 214. DOI: 10.1016/j.neuroscience.2011.08.069 [PubMed: 21924326]
- Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009; 5(12):673–681. DOI: 10.1038/nrendo.2009.212 [PubMed: 19859074]



Fig. 1. Flow chart of the RNA-Seq experiment



Fig. 2. Single-gene analysis pie chart

Dysregulated genes were involved in inflammation and stress, as well as insulin secretion.





Min6 cells were treated with vehicle or DHT for 24 minutes/24 hours. mRNA expression of target gene was normalized to that of TBP.

Author Manuscript

Author Manuscript



Fig. 4.

Based on GeneCodis3 analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, 23 significantly enriched pathways were revealed. We combined these pathways and summarized them into three biologically relevant pathways: (A) insulin secretion, (B) stress/growth factor signaling, and (C) inflammatory pathway. Red color represents upregulated genes and green color represents down-regulated genes.

| - |
|-------------------|
| |
| |
| - |
| |
| <u> </u> |
| _ |
| — |
| _ |
| |
| - |
| \mathbf{O} |
| \sim |
| _ |
| _ |
| |
| _ |
| ~ |
| |
| ~ |
| \geq |
| \geq |
| |
| a |
| lar |
| /lan |
| /lan |
| lanu |
| /lanu |
| /lanus |
| /anus |
| lanus |
| lanusc |
| Aanusc |
| /anuscr |
| Anuscr |
| / anuscri |
| Aanuscrip |
| Aanuscrip |
| Aanuscript |

Table 1

Single-gene Analysis

The table highlights 52 significant DEGs which involve inflammatory response and stress. *

| Gene Symbol | Full Name | RefSeq ID | Fold Change | FDR-adjusted p-value | Annotation |
|-------------|--|--------------|-------------|----------------------|--------------|
| Wfdc2 | WAP four-disulfide core domain 2 | NM_026323 | 11.09 | 4.24E-02 | Inflammation |
| Len2 | lipocalin 2 | NM_008491 | 10.04 | 4.28E-03 | Inflammation |
| Mmp7 | matrix metallopeptidase 7 | NM_010810 | 7.80 | 1.02E-02 | Inflammation |
| Gbp11 | predicted gene, EG634650; guanylate-binding protein RIKEN cDNA 5830443L24 gene 11; | NM_001039647 | 7.17 | 4.28E-03 | Inflammation |
| Cxcl5 | similar to LPS-induced CXC chemokine; chemokine (C-X-C motif) ligand 5 | NM_009141 | 6.16 | 4.28E-03 | Inflammation |
| Fgf21 | fibroblast growth factor 21 | NM_020013 | 4.72 | 4.28E-03 | Stress |
| Gbp10 | predicted gene, EG634650; guanylate-binding protein 10;RIKEN cDNA 5830443L24 gene | NM_001039646 | 4.69 | 4.28E-03 | Inflammation |
| Cxcl10 | chemokine (C-X-C motif) ligand 10; similar to Small inducible cytokine B10 precursor (CXCL10) (Interferon-gamma-induced protein CRG-2) (Gamma-IP10) (IP-10) (C7) | NM_021274 | 4.51 | 4.28E-03 | Inflammation |
| Gbp4 | predicted gene, EG634650; guanylate-binding protein 4 | NM_001256005 | 4.34 | 4.28E-03 | Inflammation |
| Sftpd | surfactant associated protein D | NM_009160 | 4.11 | 4.28E-03 | Inflammation |
| Gbp9 | predicted gene, EG634650; guanylate-binding protein 9, cDNA sequence BC057170 | NM_172777 | 4.10 | 4.28E-03 | Inflammation |
| Sostdc1 | sclerostin domain containing 1 | NM_025312 | 3.86 | 4.28E-03 | Stress |
| Gbp8 | predicted gene, EG634650; guanylate-binding protein 10; RIKEN cDNA 5830443L24 gene | NM_029509 | 3.80 | 4.28E-03 | Inflammation |
| Gsta4 | glutathione S-transferase, alpha 4 | NM_010357 | 3.67 | 1.77E-02 | Stress |
| Matn2 | matrilin 2 | NM_016762 | 3.44 | 4.28E-03 | Inflammation |
| Col5a2 | collagen, type V, alpha 2 | NM_007737 | 3.43 | 4.28E-03 | Stress |
| Noxa1 | NADPH oxidase activator 1 | NM_001163626 | 3.41 | 4.24E-02 | Stress |
| Gbp6 | IF116 | NM_194336 | 3.39 | 4.28E-03 | Inflammation |
| Nr0b2 | nuclear receptor subfamily 0, group B, member 2 (SHP) | NM_011850 | 3.23 | 4.28E-03 | Stress |
| Ngfr | nerve growth factor receptor (TNFR superfamily, member 16) | NM_033217 | 3.15 | 4.28E-03 | Stress |
| Reg3a | regenerating islet-derived 3 alpha | NM_011259 | 3.13 | 4.28E-03 | Inflammation |
| Klk1b8 | kallikrein 1-related peptidase b8 | NM_008457 | 3.12 | 1.54E-02 | Inflammation |
| Atf3 | activating transcription factor 3 | NM_007498 | 3.07 | 7.26E-03 | Inflammation |
| Gfra3 | glial cell line derived neurotrophic factor family receptor alpha 3 | NM_010280 | 3.01 | 4.28E-03 | Inflammation |
| Zfp36 | zinc finger protein 36 | NM_011756 | 2.96 | 4.28E-03 | Inflammation |
| Cish | cytokine inducible SH2-containing protein | NM_009895 | 2.90 | 4.28E-03 | Inflammation |
| Csf2rb | colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) | NM_007780 | 2.89 | 4.28E-03 | Inflammation |

| Gene Symbol | Full Name | RefSeq ID | Fold Change | FDR-adjusted p-value | Annotation |
|-------------|--|----------------|-------------|-----------------------------|--------------|
| Illm | interleukin 1 receptor antagonist | NM_001039701 | 2.87 | 4.28E-03 | Inflammation |
| Ifit3 | interferon-induced protein with tetratricopeptide repeats 3 | NM_010501 | 2.77 | 4.28E-03 | Inflammation |
| Lck | lymphocyte protein tyrosine kinase | NM_001162433 | 2.74 | 3.85E-02 | Inflammation |
| Gbp5 | guanylate binding protein 5 | NM_153564 | 2.58 | 4.28E-03 | Inflammation |
| Ifit1 | interferon-induced protein with tetratricopeptide repeats 1 | NM_008331 | 2.58 | 4.28E-03 | Inflammation |
| Nr5a2 | nuclear receptor subfamily 5, group A, member 2 | NM_030676 | 2.45 | 4.28E-03 | Inflammation |
| II22ra1 | interleukin 22 receptor, alpha 1 | NM_178257 | 2.40 | 4.28E-03 | Inflammation |
| Crispld2 | cysteine-rich secretory protein LCCL domain containing 2 | $NM_{-}030209$ | 2.38 | 4.28E-03 | Inflammation |
| Tnfrsf11b | tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) | NM_008764 | 2.37 | 4.28E-03 | Inflammation |
| Klk1b11 | kallikrein 1-related peptidase b11 | NM_010640 | 2.37 | 7.26E-03 | Stress |
| ligp1 | interferon inducible GTPase 1; interferon-inducible GTPase- like | NM_001146275 | 2.36 | 4.28E-03 | Inflammation |
| Rsad2 | radical S-adenosyl methionine domain containing 2 | NM_021384 | 2.34 | 4.28E-03 | Inflammation |
| Tnip3 | TNFAIP3 interacting protein 3 | NM_001001495 | 2.32 | 2.90E-02 | Inflammation |
| C4b | complement component 4B (Childo blood group) | 08780_MM | 2.25 | 4.28E-03 | Inflammation |
| C3 | complement component 3; similar to complement component C3 prepropeptide, last | NM_009778 | 2.18 | 4.28E-03 | Inflammation |
| C2cd4a | family with sequence similarity 148, member A | NM_001163143 | 2.17 | 4.28E-03 | Inflammation |
| Xaf1 | XIAP associated factor 1 | NM_001037713 | 2.16 | 4.38E-02 | Inflammation |
| Anxa1 | annexin Al | NM_010730 | 2.14 | 2.90E-02 | Inflammation |
| Sntb1 | syntrophin, basic 1 | NM_016667 | 2.13 | 7.26E-03 | Inflammation |
| Chac1 | ChaC, cation transport regulator-like 1 (E. coli) | NM_026929 | 2.13 | 1.54E-02 | Stress |
| Oasl2 | 2'-5' oligoadenylate synthetase-like 2 | NM_011854 | 2.08 | 7.26E-03 | Inflammation |
| Fgfr2 | fibroblast growth factor receptor 2 | NM_010207 | 2.07 | 4.85E-02 | Inflammation |
| Parp14 | poly (ADP-ribose) polymerase family, member 14 | NM_001039530 | 2.05 | 4.28E-03 | Inflammation |
| Tap1 | transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) | NM_001161730 | 2.05 | 4.28E-03 | Inflammation |
| Socs2 | suppressor of cytokine signaling 2; predicted gene 8000 | NM_007706 | 2.03 | 4.28E-03 | Inflammation |
| Sgk1 | serum/glucocorticoid regulated kinase 1 | NM_011361 | 2.03 | 4.28E-03 | Stress |
| F13a1 | coagulation factor XIII, A1 subunit | NM_001166391 | 0.16 | 4.28E-03 | Inflammation |
| Dapl1 | death associated protein-like 1 | NM_029723 | 0.32 | 4.28E-03 | Stress |
| MIft | myeloid leukemia factor l | NM_001039543 | 0.34 | 4.28E-03 | Inflammation |
| Lyve1 | lymphatic vessel endothelial hyaluronan receptor 1 | NM_053247 | 0.36 | 4.28E-03 | Inflammation |
| Ccdc8 | coiled-coil domain containing 8 | NM_001101535 | 0.42 | 2.57E-02 | Stress |

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Xu et al.

| $\mathbf{\Sigma}$ |
|-------------------------|
| ~ |
| <u> </u> |
| – |
| - |
| ~ |
| 0 |
| _ |
| |
| _ |
| < |
| |
| b |
| _ |
| _ |
| |
| S |
| 0 |
| |
| |
| $\overline{\mathbf{O}}$ |
| Ť. |

Author Manuscript

| RefSeq ID | Fold Change | FDR-adjusted p-value | Annotation |
|-----------|-------------|----------------------|-------------|
| NM_153175 | 0.42 | 4.28E-03 | Inflammati |
| NM_010548 | 0.43 | 4.85E-02 | Inflammatic |
| NM_029341 | 0.45 | 4.28E-03 | Inflammatic |

* Abbreviations: DEG, differentially expressed genes; FDR, false discovery rate.

melanoma associated antigen (mutated) 1-like 1

Mum111

defensin beta 1

Defb1

PR domain containing 1, with ZNF domain

Capsl Prdm1

Sele 111b

calcyphosine-like

interleukin 10

1110

selectin, endothelial cell

interleukin 1 beta

GTPase, IMAP family member 6

Gimap6

Gene Symbol Full Name

Inflammation Inflammation Inflammation

1.77E-02

0.46 0.46 0.48 0.50 0.50

NM_007548 NM_011345 NM_008361

4.28E-03 4.28E-03

3.85E-02

Inflammation Inflammation

4.28E-03

NM_001164631

NM_007843

| Gene Symbol | Full Name | RefSeq ID | Fold Change | FDR- adjusted p-value | Annotation |
|-------------|---|------------------------|-------------|-----------------------|-----------------------------|
| Sntg2 | syntrophin, gamma 2 | NM_172951 | 9.10 | 4.28E-03 | Ion Channel |
| Duox2 | dual oxidase 2 | NM_177610 | 8.29 | 4.28E-03 | Metabolism |
| Hs3st1 | heparan sulfate (glucosamine) 3-O-sulfotransferase 1 | NM_010474 | 6.28 | 4.28E-03 | Metabolism |
| Syt10 | synaptotagmin X | NM_018803 | 6.13 | 4.28E-03 | Exocytosis |
| Car2 | carbonic anhydrase 2 | 108600 ⁻ MN | 5.92 | 4.28E-03 | Glucose metabolism |
| Cftr | cystic fibrosis transmembrane conductance regulator homolog | NM_021050 | 5.42 | 4.28E-03 | Ion Channel |
| Fmol | flavin containing monooxygenase 1 | NM_010231 | 5.41 | 4.28E-03 | Metabolism |
| Rasgrp1 | RAS guanyl releasing protein 1 | NM_011246 | 5.28 | 4.28E-03 | Ras-related protein/ GTPase |
| Gpr26 | G protein-coupled receptor 26 | NM_173410 | 4.87 | 1.54E-02 | cAMP-PKA signaling |
| Kcnj5 | potassium inwardly-rectifying channel, subfamily J, member 5 | NM_010605 | 4.62 | 4.28E-03 | Membrane polarization |
| Rph3a | rabphilin 3A | NM_011286 | 4.48 | 4.28E-03 | Exocytosis |
| Hcn1 | hyperpolarization-activated, cyclic nucleotide-gated \mathbf{K} + 1 | NM_010408 | 4.12 | 4.28E-03 | Ion Channel |
| Slc39a4 | solute carrier family 39 (zinc transporter), member 4 | NM_028064 | 4.12 | 3.08E-02 | Metabolism |
| Rasl11b | RAS-like, family 11, member B | NM_026878 | 3.86 | 3.21E-02 | Metabolism |
| Grem2 | gremlin 2 homolog, cysteine knot superfamily (Xenopus laevis) | NM_011825 | 3.72 | 4.28E-03 | Metabolism |
| Lrrc55 | leucine rich repeat containing 55 | NM_001033346 | 3.46 | 4.28E-03 | Membrane polarization |
| Tph2 | tryptophan hydroxylase 2 | NM_173391 | 3.45 | 4.28E-03 | Metabolism |
| Kcnk10 | IFI16 | NM_029911 | 3.27 | 4.28E-03 | Membrane polarization |
| Hk2 | hexokinase 2 | NM_013820 | 3.21 | 4.28E-03 | Glucose metabolism |
| Tdh | L-threonine dehydrogenase; predicted gene 13929 | NM_021480 | 2.91 | 4.28E-03 | Metabolism |
| Tph1 | tryptophan hydroxylase 1 | NM_009414 | 2.87 | 4.28E-03 | Metabolism |
| Kctd14 | potassium channel tetramerisation domain containing 14 | NM_001010826 | 2.81 | 4.28E-03 | cAMP-PKA signaling |
| KIf15 | Kruppel-like factor 15 | NM_023184 | 2.73 | 4.28E-03 | Metabolism |
| Gpr126 | G protein-coupled receptor 126 | NM_001002268 | 2.67 | 4.28E-03 | cAMP-PKA signaling |
| Enpp2 | ectonucleotide pyrophosphatase/phosphodiesterase 2 | NM_001136077 | 2.65 | 4.28E-03 | cAMP-PKA signaling |
| Rerg | RAS-like, estrogen-regulated, growth-inhibitor | NM_181988 | 2.61 | 4.28E-03 | Ras-related protein/ GTPase |

J Diabetes Complications. Author manuscript; available in PMC 2018 May 01.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

The table highlights 36 significantly DEGs which involve ion channel, glucose metabolism, cAMP-PKA signaling, membrane polarization, and

Table 2

Single-gene Analysis

exocytosis.

| Gene Symbol | Full Name | RefSeq ID | Fold Change | FDR- adjusted p-value | Annotation |
|-----------------|---|----------------|-------------|-----------------------|--------------------------------|
| Pde7b | phosphodiesterase 7B | NM_013875 | 2.60 | 4.28E-03 | cAMP-PKA signaling |
| Fam13a | family with sequence similarity 13, member A | NM_153574 | 2.59 | 7.26E-03 | Ras-related protein/ GTPase |
| Cckar | cholecystokinin A receptor | NM_009827 | 2.55 | 3.98E-02 | cAMP-PKA signaling |
| Pfkfb3 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 | NM_001177752.1 | 2.54 | 4.28E-03 | Glucose metabolism |
| UGT1A1 | UDP glucuronosyltransferase 1 family, polypeptide A1 | NM_201645 | 2.48 | 4.28E-03 | Metabolism |
| Chst2 | carbohydrate sulfotransferase 2 | NM_018763 | 2.36 | 1.54E-02 | Metabolism |
| Tmc5 | transmembrane channel-like gene family 5 | NM_028930 | 2.29 | 4.28E-03 | Ion Channel |
| Adm | adrenomedullin | NM_009627 | 2.27 | 3.98E-02 | Secreted insulinotropic factor |
| Cachd1 | cache domain containing 1; similar to Cache domain containing 1 | NM_198037 | 2.20 | 7.26E-03 | Ion Channel |
| Gnb1l | guanine nucleotide binding protein (G protein), beta polypeptide 1- like | NM_023120 | 2.18 | 2.22E-02 | Ras-related protein/ GTPase |
| B3galt1 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 | NM_020283 | 2.18 | 2.78E-02 | Metabolism |
| Kcnq1 | potassium voltage-gated channel, subfamily Q, member 1; similar to Potassium voltage-gated channel, subfamily Q, member 1 | NM_008434 | 2.17 | 4.28E-03 | Membrane polarization |
| Bmp7 | bone morphogenetic protein 7 | NM_007557 | 2.15 | 4.28E-03 | Secreted insulinotropic factor |
| Hkdc1 | hexokinase domain containing 1 | NM_145419 | 2.11 | 2.90E-02 | Glucose metabolism |
| Dhrs3 | dehydrogenase/reductase (SDR family) member 3 | NM_011303 | 2.07 | 7.26E-03 | Metabolism |
| Ptger3 | prostaglandin E receptor 3 (subtype EP3) | NM_011196 | 2.07 | 1.54E-02 | cAMP-PKA signaling |
| Clic6 | chloride intracellular channel 6 | NM_172469 | 2.06 | 4.53E-02 | Ion Channel |
| Rasd2 | RASD family, member 2 | NM_029182 | 2.21 | 4.28E-03 | Ras-related protein/ GTPase |
| Ppargc1a | peroxisome proliferative activated receptor, gamma, coactivator 1 alpha | NM_008904 | 0.28 | 4.28E-03 | Glucose metabolism |
| Trpc4 | transient receptor potential cation channel, subfamily C, member 4 | NM_001253682 | 0.31 | 4.28E-03 | Ion Channel |
| Phactr3 | phosphatase and actin regulator 3 (Scapinin) | NM_001007154 | 0.38 | 1.77E-02 | Glucose metabolism |
| Rasgrf2 | RAS protein-specific guanine nucleotide-releasing factor 2 | NM_009027 | 0.38 | 4.28E-03 | Ras-related protein/ GTPase |
| Rgs7bp | regulator of G-protein signalling 7 binding protein | NM_029879 | 0.41 | 4.28E-03 | Ras-related protein/ GTPase |
| Ppp1r3c | protein phosphatase 1, regulatory (inhibitor) subunit 3C | NM_016854 | 0.42 | 3.42E-02 | Metabolism |
| Ust | uronyl-2-sulfotransferase | NM_177387 | 0.43 | 1.28E-02 | Metabolism |
| Vsn11 | visinin-like 1 | NM_012038 | 0.43 | 1.77E-02 | Ion Channel |
| Dse | dermatan sulfate epimerase | NM_172508 | 0.45 | 7.26E-03 | Metabolism |
| Gpr161 | G protein-coupled receptor 161 | NM_001081126 | 0.46 | 3.42E-02 | cAMP-PKA signaling |
| Kctd12 | potassium channel tetramerisation domain containing 12 | NM_177715 | 0.47 | 4.28E-03 | cAMP-PKA signaling |
| Hapln1 | hyaluronan and proteoglycan link protein 1 | NM_013500 | 0.49 | 1.28E-02 | Metabolism |

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Significantly Enriched KEGG Pathways.*

| Dotherow | Dethurov ID | D Victure | 5000 J # |
|--|-------------|-----------|----------|
| t aurway | I autway IL | T value | |
| Cytokine-cytokine receptor interaction | Kegg:04060 | 5.78E-06 | 11 |
| Jak-STAT signaling pathway | Kegg:04630 | 2.68E-04 | 7 |
| Tryptophan metabolism | Kegg:00380 | 4.48E-04 | 4 |
| Butirosin and neomycin biosynthesis | Kegg:00524 | 6.47E-04 | 2 |
| Glycosphingolipid biosynthesis - lacto and neolacto series | Kegg:00601 | 1.07E-03 | 3 |
| Cell adhesion molecules (CAMs) | Kegg:04514 | 1.15E-03 | 9 |
| Leishmaniasis | Kegg:05140 | 1.85E-03 | 4 |
| African trypanosomiasis | Kegg:05143 | 2.01E-03 | 3 |
| Gastric acid secretion | Kegg:04971 | 2.57E-03 | 4 |
| Osteoclast differentiation | Kegg:04380 | 2.63E-03 | 5 |
| Bile secretion | Kegg:04976 | 2.70E-03 | 4 |
| Complement and coagulation cascades | Kegg:04610 | 3.46E-03 | 4 |
| Fructose and mannose metabolism | Kegg:00051 | 3.63E-03 | 3 |
| Insulin signaling pathway | Kegg:04910 | 5.02E-03 | 5 |
| Hepatitis C | Kegg:05160 | 5.18E-03 | 5 |
| Malaria | Kegg:05144 | 5.49E-03 | ю |
| MAPK signaling pathway | Kegg:04010 | 5.96E-03 | 7 |
| Starch and sucrose metabolism | Kegg:00500 | 6.22E-03 | 3 |
| Glycosphingolipid biosynthesis - globo series | Kegg:00603 | 6.44E-03 | 2 |
| Glycosaminoglycan biosynthesis - keratan sulfate | Kegg:00533 | 6.44E-03 | 2 |
| Type II diabetes mellitus | Kegg:04930 | 7.84E-03 | 3 |
| Staphylococcus aureus infection | Kegg:05150 | 7.84E-03 | ю |
| Pancreatic secretion | Kegg:04972 | 9.40E-03 | 4 |
| - | | | |

J Diabetes Complications. Author manuscript; available in PMC 2018 May 01.

 $\overset{*}{}_{\rm Abbreviations:\, KEGG,\, Kyoto\, Encyclopedia of Genes and Genomes.$

| - |
|------------------|
| |
| ~ |
| - |
| _ |
| — |
| - |
| _ |
| $\overline{}$ |
| \mathbf{O} |
| _ |
| |
| |
| \sim |
| |
| ~ |
| \geq |
| |
| a |
| /lar |
| /lan |
| /anu |
| /lanu |
| /lanus |
| /lanus |
| lanus |
| Anusc |
| lanuscr |
| / anuscri |
| /anuscrip |
| /anuscrip |

Table 4

GO Analysis*

A total of 43, 17, and 23 BP, CC and MF categories were detected significantly enriched (FDR<0.05) by GeneTrail and GeneCoDis3. Among them, representative GO categories include (i) BP: "inflammatory response", "ion transport" and "insluin secretion" (ii) CC: "extracellular region", "extracellular space" and "integral to membrane", and (iii) MF: "GTPase activity", "calcium ion binding", and "GTP binding", respectively.

| GO Category | GO ID | GO Name | GeneTrail # Genes | GeneTrail FDR | GeneCoDis3 # Genes | GeneCoDis3 FDR |
|-------------|------------|--|-------------------|---------------|--------------------|----------------|
| BP | GO:0006950 | response to stress | 35 | 2.09E-05 | 5 | 3.92E-02 |
| BP | GO:0005975 | carbohydrate metabolic process | 16 | 4.50E-04 | 6 | 0.0380599 |
| BP | GO:0030073 | insulin secretion | 7 | 7.59E-04 | 4 | 1.04E-02 |
| BP | GO:0006954 | inflammatory response | 12 | 8.04E-04 | 10 | 5.56E-04 |
| BP | GO:0006811 | ion transport | 21 | 8.98E-04 | 15 | 4.80E-03 |
| BP | GO:0040008 | regulation of growth | 11 | 4.32E-03 | 4 | 2.82E-02 |
| BP | GO:0007155 | cell adhesion | 16 | 5.15E-03 | 11 | 2.65E-02 |
| BP | GO:000968 | negative regulation of signal transduction | 5 | 1.06E-02 | 4 | 1.88E-02 |
| BP | GO:0006915 | apoptosis | 18 | 2.33E-02 | 12 | 2.28E-02 |
| BP | GO:0032870 | cellular response to hormone stimulus | 4 | 0.0467718 | 2 | 0.0285125 |
| cc | GO:0016021 | integral to membrane | 81 | 1.62E-03 | 79 | 2.19E-06 |
| cc | GO:0008076 | voltage-gated potassium channel complex | 4 | 1.65E-02 | 4 | 1.72E-02 |
| cc | GO:0005576 | extracellular region | 51 | 2.81E-10 | 44 | 1.75E-12 |
| cc | GO:0005887 | integral to plasma membrane | 11 | 4.91E-02 | 13 | 1.53E-03 |
| MF | GO:0003924 | GTPase activity | 8 | 1.10E-03 | 8 | 4.48E-03 |
| MF | GO:0005249 | voltage-gated potassium channel activity | 5 | 1.13E-02 | 4 | 4.13E-02 |
| MF | GO:0005215 | transporter activity | 24 | 1.15E-03 | 7 | 2.24E-02 |
| MF | GO:0005216 | ion channel activity | 10 | 1.44E-02 | 6 | 2.26E-02 |
| MF | GO:0005509 | calcium ion binding | 13 | 6.47E-03 | 17 | 2.04E-04 |
| MF | GO:0004396 | hexokinase activity | 2 | 9.44E + 01 | 2 | 2.14E-02 |
| MF | GO:0005525 | GTP binding | 10 | 9.44E-03 | 10 | 1.69E-02 |
| MF | GO:0005267 | potassium channel activity | 9 | 9.64E-03 | 4 | 4.44E-02 |

J Diabetes Complications. Author manuscript; available in PMC 2018 May 01.

both programs. GO terms are first sorted by "GO Category" in ascending order, then by "GeneTrail FDR" in ascending order, and then by "GeneCoDis3 FDR" in ascending order.